Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Subscribe To Our Newsletter & Stay Updated